BHCUX Mutual Fund

NAV$22.16

Fund Essentials - as of Mar 31, 2026

Net Assets
-
Expense Ratio
0.85%
Dividend Yield (Current)
-
Holdings
41
Inception Date
Apr 30, 2018
Fund Family
Baron Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Unspecified

Performance

YTD+4.05%
1 Year+24.20%
3 Year+5.67%
5 Year+1.56%

Asset Allocation

Stocks: 100.00%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly And Company9.95%
AZN:LNAstrazeneca Plc Adr5.09%
JNJJOHNSON AND JOHNSON4.58%
TMOThermo Fisher Scientific Inc4.25%
MTDMettler-Toledo International, Inc.3.99%
Top 10 Concentration: 43.86%Report Date: Mar 31, 2026
Download all 41 holdings for BHCUX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Unspecified
Latest Distribution
$0.22
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how BHCUX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

BHCUX Mutual Fund Overview

BHCUX Mutual Fund (Baron Health Care Fund Class R6) is managed by Baron Funds. BHCUX expense ratio is 0.85%, holding 41 positions across sectors including Health Care, Unknown, Real Estate. Inception date: 2018-04-30.

BHCUX performance shows a YTD return of 4.05%. The 1-year return is 24.20% and the 5-year return is 1.56%.

BHCUX top holdings include Eli Lilly And Company (9.9%), Astrazeneca Plc Adr (5.1%), JOHNSON AND JOHNSON (4.6%), Thermo Fisher Scientific Inc (4.3%), Mettler-Toledo International, Inc. (4.0%). View all BHCUX holdings, sector breakdown, or dividend history.

BHCUX can be compared against other funds using the overlap calculator or side-by-side comparison tool. BHCUX alternatives are available via the screener, along with tax-loss harvesting opportunities.